Clinical Development of imiquimod based immunotherapy (KS01*)

• Subject Area: Dermatology ; Rheumatology
• Term: from 2019 to 2023
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 246807620

In the project we will develop an imiquimod based transcutaneous immunization method (TCI) and characterized mechanisms for T cell activation in mice. For clinical translation, we are conducting a study with the novel imiquimod formulation IMI-Gel in patients with actinic keratosis to investigate tolerability and local inflammatory reactions. The results will reveal the applicability of IMI-Gel in humans and demonstrate similarities and differences of imiquimod induced skin changes between mice and man. Our prospective aim is to conduct a TCI trial in humans with HPV infections.

• DFG Programme: CRC/Transregios
• Subproject of: TRR 156: The skin as sensor and effector orchestrating local and systemic immunity
• Applicant Institution: Ruprecht-Karls-Universität Heidelberg
• Project Head: Professor Dr. Markus P. Radsak